Antibody-drug conjugates: the target chemotherapy of szolid tumors

The antibody-drug conjugates are the most dynamically developping field in oncology beside the immunotherapy. Although their introduction started in hemato-oncology, today these new agents reshape the treatment of various solid tumors. Meanwhile, the efficacy of ADCs strongly depends on the target tumor-antigen. Since the first ADCs targetted to HER2 antigen, the accompanying diagnostic algorythm was already provided. However, the later developed new ADC forms the tumor selectivity of the antigens is not evident and the development of predictive marker tests frequently lagged behind clinical introduction. It would be wise to learn from the clinical development of target therapies (antitumor antibodies or mutant oncogen inhibitors) which provided evidences that these novel agents are most effective clinically when the tumor type is selected and/or the gene mutation is present in the cancer.